Lithium, but not fluoxetine or the CRF₁ receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus

Authors: Nicola D. Hanson, Charles B. Nemeroff, Michael J. Owens

Addresses: Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 100 Woodruff Cir, Suite 4000, Atlanta GA 30322 (NDH, MJO); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, 1120 NW 14th St, Miami FL 33136 (CBN)
Running title: Lithium, fluoxetine, and R121919 in neurogenesis

Corresponding author: Michael J. Owens, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 100 Woodruff Cir, Suite 4000, Atlanta GA 30322

mowens@emory.edu T: (404) 727-4059 F: (404) 727-3233

Number of text pages: 28

Number of tables: 2

Number of figures: 3

Number of references: 44

Number of words in abstract: 168

Number of words in introduction: 646

Number of words in discussion: 1049


Section assignment: Neuropharmacology
Abstract

Several antidepressant drugs have previously been reported to increase neurogenesis in the dentate gyrus of the hippocampus in laboratory animals. We found no effect of the selective serotonin reuptake inhibitor (SSRI) fluoxetine or the CRF₁ (corticotropin-releasing factor receptor 1) antagonist R121919 on the rate of cell proliferation or hippocampal BDNF (brain-derived neurotrophic factor) mRNA expression in either adult or adolescent rats following chronic administration. In adults, the mood stabilizer lithium was found to significantly increase cell proliferation; the atypical antipsychotic paliperidone did not affect proliferation, either alone or when combined with lithium. Fourteen-day survival of neuronally-fated cells showed a significant interaction effect of lithium and paliperidone but no effect of either drug alone. BDNF mRNA expression was significantly decreased by lithium in the CA1/2 cell fields and increased by paliperidone in the CA1/2, CA3, and dentate gyrus. These results raise questions concerning the hypothesis that all antidepressants increase neurogenesis under nonstressed conditions. They also confirm and extend previous reports of lithium-induced increases in cell proliferation but not survival.
Introduction

Monoaminergic-acting antidepressants, as a class, have been hypothesized to upregulate several processes involved in hippocampal neurogenesis, including neural progenitor cell (NPC) proliferation, short- and long-term survival of neuroblasts and immature neurons, expression of neurotrophic factors, and growth and branching of neuronal processes. NPC proliferation rate and immature neuron survival rate have been upregulated by fourteen or more days of treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine, but not by shorter regimens (Malberg et al., 2000; Kodama et al., 2004; Huang and Herbert, 2006; Marcussen et al., 2008), though this effect has not been universally observed (Cowen et al., 2008; David et al., 2009). Experiments involving the SSRI citalopram/escitalopram have been less successful, with negative results outnumbering positive ones regarding both proliferation and survival (Jaakomovits et al., 2006; Jayatissa et al., 2006). The tricyclic antidepressant imipramine, though less frequently used in studies of neurogenesis, has been shown to positively impact both proliferation and survival (Keilhoff et al., 2006; Surget et al., 2008).

Additionally, CRF₁ receptor antagonists, which have recently been explored clinically as alternatives to conventional monoaminergic antidepressants (reviewed in Holsboer and Ising, 2008), have also been hypothesized to upregulate hippocampal neurogenesis. One CRF₁ receptor antagonist, SSR125543, has been reported by two groups to block stress-induced deficits in cell proliferation, though it did not affect cell proliferation under non-stressed conditions (Alonso et al., 2004; Surget et al., 2008). The CRF₁ antagonist used in experiments here, R121919 (3-[6-(dimethylamino)-4-methylpyridin-3-yl]-2,5-dimethyl-N,N-dipropyl-1H-pyrazolo[1,5-a]pyrimidin-8-ium-7-amine; also known as NBI 30775; PubChem compound ID 44400634;
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pccompound&term=r121919), has been shown to attenuate both behavioral and endocrine responses to stress in rats (Gutman et al., 2003; Rivier et al., 2003). There are no reports of the effects of R121919 on neurogenesis.

A series of experiments involving the mood stabilizer lithium augmented with the atypical antipsychotic paliperidone (9-hydroxyrisperidone) are included in this report. The rationale for performing these experiments arises from the common clinical practice of using antipsychotic augmentation in the treatment of refractory bipolar and unipolar depression, a regimen that has been shown to be effective in controlled studies (Ghaemi and Goodwin, 1999; Rothschild, 2003). Moreover, both atypical antipsychotics and lithium are effective in augmenting the effects of antidepressants in non-responders (Simon and Nemeroff, 2005; Rapaport et al., 2006; Keitner et al., 2009; Nelson and Papakostas, 2009) and similarly, atypical antipsychotics augment the therapeutic effects of lithium (Bowden, 2005). The mechanism(s) underlying these augmenting effects of atypical antipsychotics remain uncertain, although electrophysiological studies have found several atypical antipsychotics to increase firing rates of noradrenergic neurons in the locus coeruleus in opposition to the decrease in firing caused by SSRIs (Seager et al., 2005; Dremencov et al., 2007a; Dremencov et al., 2007b). If neurogenesis plays a crucial role in the therapeutic effects of antidepressants and mood stabilizers, it is plausible that the effects of atypical antipsychotics in augmenting these drugs may also be mediated by a change in neurogenesis.

In laboratory animals, chronic lithium treatment has been shown to increase both cell proliferation and survival (Chen et al., 2000; Son et al., 2003; Silva et al., 2008). The atypical antipsychotic olanzapine has been reported to increase the rate of cell proliferation in the dentate gyrus with an effect size similar to fluoxetine, though combination olanzapine-fluoxetine
treatment did not increase the rate of neurogenesis above that observed with fluoxetine alone (Kodama et al., 2004). Other atypical antipsychotics reported to increase hippocampal neurogenesis include clozapine, quetiapine, and risperidone (Wakade et al., 2002; Halim et al., 2004; Luo et al., 2005). Furthermore, following chronic restraint stress, quetiapine and venlafaxine exhibit additive effects on neurogenesis (Xu et al., 2006). However, numerous studies have reported no effects of atypical antipsychotics on hippocampal neurogenesis (Wakade et al., 2002; Green et al., 2006).

These experiments were undertaken to test the hypothesis that all medications with utility in treating depression, with distinct mechanisms of action, share the common feature of augmenting neurogenesis and/or neuronal survival.

**Methods**

**Animals**

Adult male Sprague-Dawley rats, approximately eight weeks old in the adult experiments or three weeks old in the adolescent experiment, were obtained one week prior to initiation of the experimental protocols (Charles River, Wilmington MA). Animals were maintained in standard laboratory conditions: pair-housed in polycarbonate cages (30 x 20 x 20 cm) with corn cob bedding, on a 12:12 light cycle, with *ad libitum* access to food and water. All procedures used were approved by the Institutional Animal Care and Use Committee (IACUC) of Emory University and are in compliance with National Institutes of Health (NIH) guidelines for the care and use of laboratory animals.

**Drug administration**
Fluoxetine (11 mg/kg as fluoxetine HCl) or R121919 (30 mg/kg, donated by Neurocrine Biosciences) were administered as oral gavage in water once daily for three weeks, with precise dose matched to each animal’s body weight within the last three days. Control animals were administered the corresponding volume of water. These doses were chosen because they are both behaviorally active and mimic therapeutic serum concentrations (fluoxetine) or provide robust CRF₁ receptor occupancy (R121919; Gutman et al., 2003).

Paliperidone (0.75 mg/kg/day, supplied by Janssen) or vehicle (0.3% tartaric acid) were delivered by subcutaneous osmotic minipumps (Alzet model 2ML4, Durect Corporation, Cupertino CA). Although risperidone has a longer history of use as an atypical antipsychotic, paliperidone represents ~90% of the active drug following systemic risperidone administration. Additionally, the solubility characteristics of paliperidone were superior to risperidone for use in chronic dosing studies (MJ Owens, unpublished observations). After recovering from implantation surgery, animals were administered chow containing 1.2 g/kg lithium carbonate for one week, followed by chow containing 2.4 g/kg lithium carbonate, or control chow (Bio-Serv, Frenchtown NJ). This regimen continued for three weeks total for the cell proliferation experiment and four weeks total for the cell survival experiment. Animals receiving lithium chow were provided with 0.9% NaCl in water in order to minimize hyperurica. These doses of lithium were chosen to mimic therapeutic serum concentrations.

Serum drug analysis was performed by the lab of Dr. James C. Ritchie (Core and Toxicology Laboratories, Emory University Hospital) for fluoxetine and lithium, and by the lab of Drs. Jennifer Donovan and Lindsay DeVane (Medical University of South Carolina) for paliperidone. Serum concentrations of R121919 were not measured, due to its short half-life and
unknown identity of possible active metabolites but dosing was based upon our previous experience (Gutman et al., 2003).

**BrdU administration and sacrifice**

Bromodeoxyuridine (BrdU, 200 mg/kg in 0.9% saline, Sigma-Aldrich, St. Louis, MO) was administered via a single *ip* injection according to the timelines given for each experiment. For assessment of cell proliferation rate, BrdU injection was given on day 21 or 22 of drug administration and animals were killed 24 (in the fluoxetine and R121919 experiments) or 2 (in the lithium and paliperidone experiment) hours later. For assessment of newborn cell survival in the lithium and paliperidone experiment, BrdU injection was given on day 14 or 15 of drug administration and animals were killed 14 days later. At the time of death, animals were deeply anesthetized with pentobarbital and transcardially perfused with cold 0.1M phosphate buffered saline (PBS) followed by 4% paraformaldehyde. At the time of cardiac puncture, blood was collected for serum drug analysis. The brains were removed, post-fixed overnight, and equilibrated in a 30% sucrose solution. Sections of 25 μm through the entire hippocampus (bregma –2.4 to –6.2 mm) were cut on a cryostat and mounted on slides for ICC and *in situ* hybridization procedures.

**Immunocytochemistry**

Immunocytochemical staining was performed on every twelfth section throughout the hippocampus. For BrdU staining, antigen retrieval was performed by incubation in 50% formamide/SSC at 65°C, followed by 2M HCl at 37°C, and then neutralization in 0.1 M boric acid (pH 8.5). For Ki-67 staining, antigen retrieval was performed by incubation in 10 mM citrate buffer at 90°C. After quenching in 2% hydrogen peroxide, sections were blocked in 3% normal horse serum (Vector, Burlingame, CA) and incubated overnight in 1:100 mouse
monoclonal anti-BrdU antibody (Becton-Dickinson, Franklin Lakes, NJ) or 1:100 mouse monoclonal anti-Ki-67 antibody (Vector). The next day, they were treated with 1:200 horse anti-mouse rat-adsorbed secondary antibody, then treated with a Vectastain ABC kit and visualized with DAB substrate (all Vector).

Stained sections were examined at 40x magnification under a light microscope. Labeled cells were counted if they were within the subgranular zone of the dentate gyrus or within one cell width from its edge. A total number of positively labeled cells was acquired for each animal and multiplied by 12 to approximate the number of labeled cells throughout the entire dentate gyrus. Additionally, cell counts were divided into dorsal and ventral parts of the dentate gyrus. This procedure follows established guidelines for unbiased rare event stereology (Mouton, 2002). All cell counting was performed by the same individual under treatment-blind conditions.

A Student’s t-test (for each group of the fluoxetine / R121919 experiments) or two-way ANOVA (for the lithium / paliperidone experiment) was performed on each of the resulting measures, with total dentate gyrus and dorsal and ventral regions considered separately. The criterion for significance was p < .05. Additionally, when BrdU and Ki-67 cell counts were available for the same animal cohorts, these individual points, ungrouped by treatment, were subjected to correlations analysis (Pearson’s r). As both numbers represent the same population of proliferating cells, these numbers should correlate strongly.

**In situ hybridization**

BDNF mRNA was quantified using *in situ* hybridization with an $^{35}$S-labeled riboprobe. As in the immunocytological protocol above, every twelfth section was treated and analyzed. BDNF riboprobe was constructed from cDNA inserts including the full coding regions plus some flanking sequence, ligated into a pR1112-8 plasmid. Radiolabeled antisense cRNA was
synthesized by incorporating $[^{35}\text{S}]-\text{CTP}$ into the probe. The transcription reaction was performed utilizing an Ambion MAXIscript kit with T3 RNA polymerase (Applied Biosystems, Foster City, CA), according to the instructions provided. Following transcription and removal of the cDNA template with DNase, the cRNA probe was recovered through gel filtration using a G-50 Sephadex Quick Spin column (GE Healthcare, Piscataway, NJ).

The slides underwent 10 minutes of acetylation (0.5% acetic anhydride in 0.1 mol/L triethanolamine, pH 8.0), two rinses in 2X SSC, and dehydration through a graded ethanol series. The sections were then air-dried for at least one hour prior to hybridization. The brain sections were hybridized overnight at 60°C with 1 - 2 x 10^6 cpm of $[^{35}\text{S}]-\text{labeled cRNA probe diluted into hybridization buffer (50\% formamide, 10\% dextran sulfate, 0.3 M NaCl, 1X Denhardt’s solution, 10 mM Tris, 1 mM ethylenediaminetetraacetic acid (EDTA), 2 mg/ml yeast tRNA, 10 mM dithiothreitol [DTT]) in humidified Nunc trays.}

The next day, slides were allowed to cool to room temperature before being washed four times in 4X saline-sodium citrate buffer (SSC). The sections were then treated with 250 $\mu$g/ml RNase A for 30 minutes at 37°C. Subsequently, the slides underwent a series of SSC washes (supplemented with 1 mM DTT) with salt concentrations decreasing from 2X to 0.5X, followed by a 60 minute high stringency wash with 0.1X SSC + 1mM DTT at 60°C, then dehydration through a graded ethanol series. The slides were air-dried and then apposed to Kodak Biomax MR film until signal reached the desired intensity.

Images on film were digitized with a CCD-72 camera and image analysis system (Dage-MTI, Michigan City IN). Semiquantitative analysis was performed using AIS software. Messenger RNA expression levels were calculated by subtracting the neutral background density from the specific signal. Sections were matched for rostrocaudal level and analyzed for values...
representing the regions CA1/2, CA3, and dentate gyrus, which were then averaged between sections to produce a single value for each region for each animal.

A Student’s t-test (for each group of the fluoxetine / R121919 experiment) or two-way ANOVA (for the lithium / paliperidone experiment) was performed on each of the resulting measures, with total dentate gyrus and dorsal and ventral regions considered separately. The criterion for significance was p < .05.

Results

Fluoxetine and R121919

In a pilot study in adult animals, chronic daily dosing of the chosen fluoxetine dosage produced reliable serum concentrations in a narrow range of 600-700 ng/ml (combined fluoxetine plus its active metabolite norfluoxetine) at 18 hours past dose time. This represents approximately the 80-85\textsuperscript{th} percentile for patients treated with fluoxetine at our site (Drs. Zachary N. Stowe and James C. Ritchie, Emory University, unpublished observations). The timing of daily dosing for the experiment resulted in animals that were past drug nadir at the time of sacrifice, thus serum concentrations were not measured. In rats, the half-life of fluoxetine is \~2 hours and the half-life of norfluoxetine, which possesses identical pharmacology (Owens et al; 1997), is \~30 hours (MJ Owens, unpublished data). The dose-serum concentration relationship for fluoxetine + norfluoxetine has been experimentally shown to be equivalent in adult and adolescent rats (Dr. Gretchen Neigh, Emory University, personal communication).

In adult animals, no effect of either fluoxetine or R121919 on cell proliferation (as measured by 24-hour BrdU incorporation) was seen in either the total, dorsal, or ventral dentate gyrus (Table 1). No effect of either drug on BDNF mRNA expression was observed in any hippocampal area (Table 2).
In adolescent animals, no effect of either fluoxetine or R121919 on cell proliferation (as measured by 24-hour BrdU incorporation or Ki-67 expression) was noted in either the total, dorsal, or ventral dentate gyrus (Table 1). Correlation analysis of Ki-67 vs BrdU cell counts revealed a strong linear correlation ($r=0.5461; p<0.0001$) with a slope of $0.2669 \pm 0.05423$. No effect of either drug on BDNF mRNA expression was seen in any hippocampal area (Table 2).

**Lithium and paliperidone**

Animals with serum lithium concentrations under 0.40 mM were excluded (2 of 48 total animals); serum concentrations of lithium in remaining animals averaged 0.62 mM in the cell proliferation experiment and 0.67 mM in the cell survival experiment. These concentrations are within the clinical therapeutic range. Animals with serum paliperidone concentrations under 20 ng/ml were excluded (4 of 48 total animals); serum concentrations of paliperidone in remaining animals averaged 66 ng/ml in the proliferation experiment. In the cell survival experiment, serum concentrations of paliperidone varied greatly between those animals receiving paliperidone only and those also receiving lithium: paliperidone only animals averaged 74 ng/ml while Li + Pal animals averaged only 31.4 ng/ml. Because the lithium groups in the survival experiment exhibited greater urination than did the lithium groups in the proliferation experiment (we hypothesize this was due to the longer length of lithium treatment), we suspect that this affected the rate of paliperidone excretion in these animals (Mannens et al., 1993). Mean peak to trough ratio of paliperidone in humans is 1.7 (Invega package insert) with the trough 75th percentile of serum concentrations being 52 ng/ml (middle 50th percentile 20-52 ng/ml; Nazirizadeh et al., 2010).

A significant effect of lithium was observed on cell proliferation (as measured by 24-hour BrdU incorporation) in all areas ($p<0.0001$ for total; $p=0.0052$ for dorsal; $p=0.0005$ for ventral);
no effect of paliperidone was observed (Figure 1). 14-day cell survival (as measured by 14-day BrdU incorporation) showed a significant interaction effect of lithium plus paliperidone in the total and ventral measurements, such that the combination decreases proliferation relative to either drug alone (p=0.0295 and p=0.0156 respectively). There was a trend for increased cell number in the lithium and paliperidone alone groups which decreased to a level similar to control in the lithium/paliperidone combination group (Figure 2).

BDNF mRNA expression was negatively affected by lithium in the CA1/2 and CA3 (p<0.0001 and p=0.0003, respectively), positively affected by paliperidone in the CA1/2, CA3, and dentate gyrus (p=0.0002, p<0.0001, p=0.006), and showed a drug interaction effect in the CA1/2 (p=0.001) (Figure 3). The BDNF data were taken from the cell proliferation experiment, in which serum paliperidone concentrations were similar between the paliperidone only and the li + pal groups.

Discussion

As noted earlier, these experiments were undertaken to test the hypothesis that all medications with efficacy in treating depression, even when possessing different initial mechanisms of action, share the common feature of augmenting neurogenesis and/or neuronal survival. The failure of chronic fluoxetine treatment to increase cell proliferation rate was quite surprising. Because the extant literature reported this consequence of long-term fluoxetine treatment to be a reliable function, this SSRI treatment group was originally included as a positive control in our experiments. However, after lack of success in producing the expected result, communications between our group and researchers from other laboratories revealed that many had experienced similar difficulties in reproducing this effect. Most of these negative results have not been published, with notable exceptions involving fluoxetine in two studies and
citalopram in a third (Jaako-Movits et al., 2006; Cowen et al., 2008; David et al., 2009; it is important to note that each of these studies also used behaviorally active antidepressant doses).

The fact that fluoxetine did not produce changes in cell proliferation despite the use of a dose that has reported to be behaviorally active effects and at clinically therapeutically relevant concentrations, suggests that it is not a simple problem with drug administration or a fluke experiment that is responsible for this deviation from the prevailing dogma of antidepressant effects on neurogenesis. Rather, it is likely that some finer point related to the stress levels or previous experiences of the animals involved determines their responsiveness to antidepressant effects. These factors might include housing conditions, ambient noise level, personnel activity, conditions related to shipping or breeding colony, or any number of small details which are impossible to entirely control even at the hands of researchers skilled in minimizing laboratory stress conditions. Early life stress, which might have occurred under the domain of the breeding facility, has been shown to greatly reduce responsivity of adult neurogenesis to both stress and antidepressant treatment (Mirescu et al., 2004; Navailles et al., 2008). Some studies testing the same drugs under both stressed and non-stressed conditions report that an antidepressant regimen which does not alter neurogenesis under non-stressed conditions will fully or partially block the decrease caused by stress (Jaako-Movits et al., 2006). This raises the possibility that successful experiments may require a certain level of stress and that expertise in minimizing laboratory stress conditions might actually be a hindrance in replicating these experiments. Whatever the key factor(s) might be between laboratories which are responsible for these discordant results, alteration of neurogenesis is clearly not a reliable effect of behaviorally active doses of antidepressants.
The failure of the CRF$_1$ antagonist R121919 to produce an effect, while confounded by the same issues discussed for the antidepressants above, is not surprising. Of the two reports of the effects of CRF$_1$ antagonists on cell proliferation under non-stressed conditions, both were in agreement with these results in finding no change (Alonso et al., 2004; Surget et al., 2008). Moreover, the behavioral antidepressant effects of a CRF$_1$ antagonist have been observed even when hippocampal neurogenesis is ablated by x-irradiation or methylazoxymethanol; this suggests that neurogenic actions of these drugs are not necessary for their antidepressant effects (Surget et al., 2008; Bessa et al., 2009). Other recent evidence also supports the hypothesis that neurogenesis may not in itself be necessary for antidepressant action and may simply occur in association with other features of neuroplasticity which are closely tied to antidepressant effects (Bessa et al., 2009).

In the lithium and paliperidone experiments, the primary finding was a robust effect of chronic lithium treatment on NPC proliferation rate; in contrast, paliperidone had no appreciable effect either alone or as an augmentation to lithium treatment. Interestingly, when the newborn cells were followed to two weeks post-generation with continuing drug exposure, the lithium effect was lost. This suggests that, although lithium increases proliferation rate, there is a corresponding increase in rate of cell death of this newborn cell population which results in no net gain in new cell number at two weeks of age. One report that chronic lithium treatment increases apoptosis as well as cell proliferation in the dentate gyrus supports this interpretation (Silva et al., 2008). For adult-generated granule cells, the first few weeks of life have been established as crucial in establishing connections to reach functional maturity and enable survival (Dayer et al., 2003). It may therefore be beneficial to have a larger pool of immature neurons
from which the most successfully integrated may be selected, though the resulting number of mature neurons is unchanged.

It should be noted that animals on a lithium diet stabilized at a body weight averaging 10-15% less than animals on a standard chow diet, though they maintained similar standards of general health. This was presumably due to the tendency of animals presented with ad libitum chow to eat slightly less (approximately 6%) of the lithium-containing chow, which was nutritionally equivalent to the control chow (data from pilot animals, not shown). This is common and expected for the dosages used (Dr. Husseini Manji, Johnson & Johnson, personal communication). There is thus the small possibility that the effect of lithium on proliferation rate observed here is not truly a drug effect but is related to the decreased food intake and/or corresponding decreased growth of body mass. There is some evidence for increased neurogenesis under calorie-restricted conditions, but only when total caloric intake is reduced much more than the 6% seen here (Kwon et al., 2008).

The failure of paliperidone to increase either proliferation or survival of new hippocampal neurons was somewhat surprising, considering reported efficacy of atypical antipsychotic treatment in bipolar disorder and as augmenting agents in refractory depression. This suggests that treatment of bipolar disorder and/or refractory depression with atypical antipsychotics likely involves crucial pathways distinct from neurogenesis. The paliperidone-induced increase of BDNF mRNA in the CA1/2 and CA3 of the hippocampus seen here may be one contributing factor. BDNF mRNA expression levels often, but do not always, correlate with the rate of neurogenesis in the hippocampus, and BDNF/TrkB signaling is theorized to play a positive role in general neuroplasticity (Schmidt and Duman, 2007). Here, the disconnect between cell proliferation rate and BDNF expression is glaring, as BDNF expression is increased
only in the case of paliperidone treatment alone and normalizes with the addition of lithium.
Acknowledgements

The authors wish to thank the laboratories of James C. Ritchie, Ph.D., Emory University, and Jennifer Donovan, Ph.D. and Lindsay DeVane, Pharm.D., Medical University of South Carolina, for the performance of serum drug analyses. We also thank Ronald Duman, Ph.D., Yale University, for his thoughtful contributions to the design and interpretation of these studies.
Authorship contributions

Participated in research design: Hanson, Nemeroff, and Owens.

Conducted experiments: Hanson.

Contributed new reagents or analytic tools: None.

Performed data analysis: Hanson.

Wrote or contributed to the writing of the manuscript: Hanson, Nemeroff, and Owens.

Other: None.
References


Footnotes

This work was supported by the National Institutes of Health National Institute of Mental Health [Grant 42088]; National Institutes of Health National Institute on Drug Abuse [Grant 15040]; and Janssen Pharmaceutica.

Parts of the work presented in this manuscript have previously appeared in the doctoral dissertation of Nicola D. Hanson (Division of Biological and Biomedical Sciences, Emory University) and in the following poster abstracts:


Hanson ND, Brotherton TE, Nemeroff CB, Owens MJ (2007) Paliperidone does not augment effects of lithium on cell proliferation in the dentate gyrus. Society for Neuroscience 37th annual meeting, 267.5.

Reprint requests should be directed to: Michael J. Owens, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 100 Woodruff Cir, Suite 4000, Atlanta GA 30322 mowens@emory.edu
Figure 1. Chronic treatment with lithium but not paliperidone significantly increased cell proliferation rate (measured using two-hour BrdU incorporation) in the dentate gyrus of adult rats. Two-way ANOVA revealed significant effect of lithium in all areas (p<0.0001 for total; p=0.0052 for dorsal; p=0.0005 for ventral). n=12 for lithium group; n=8 for each other group. Data are presented as mean ± SEM.

Figure 2. Chronic treatment with lithium and/or paliperidone produced an interaction effect but no significant effect of either drug on BrdU cell counts indicating 14-day cell survival rate in the dentate gyrus. Two-way ANOVA revealed significant interaction effect for total and ventral areas (p=0.030 and p=0.016 respectively). n=12 for control and lithium groups; n=8 for paliperidone and pal+li groups. Data are presented as mean ± SEM.

Figure 3. Chronic treatment with lithium and/or paliperidone produced opposing effects on expression of BDNF mRNA. Two-way ANOVA revealed significant effects of lithium, paliperidone, and interaction in CA1/2 (**p≤0.001, ***p<0.001); significant effects of lithium and paliperidone in CA3 (p=0.0003, p<0.0001); and significant effect of paliperidone in the dentate gyrus. n=12 for lithium group; n=8 for each other group. ROD = relative optical density. ns = not significant. Data are presented as mean ± SEM.
### Table 1.

Chronic treatment with fluoxetine or R121919 did not affect cell proliferation rate (measured using 24-hour BrdU incorporation or endogenous Ki-67 expression) in the dentate gyrus of adult or adolescent rats. Data are presented as number of labeled cells within the entire dentate gyrus and its dorsal and ventral parts ± SEM. n=8-12 for all groups.

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Dorsal</th>
<th>Ventral</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vehicle</td>
<td>Fluoxetine</td>
<td>R121919</td>
</tr>
<tr>
<td>Adult (BrdU)</td>
<td>1967±174</td>
<td>1983±173</td>
<td>1812±118</td>
</tr>
<tr>
<td>Adolescent (BrdU)</td>
<td>4691±319</td>
<td>4659±479</td>
<td>5320±655</td>
</tr>
<tr>
<td>Experiment 1</td>
<td>6230±332</td>
<td>5828±366</td>
<td>5072±359</td>
</tr>
<tr>
<td>Adolescent (BrdU)</td>
<td>14710±807</td>
<td>15931±736</td>
<td>16817±903</td>
</tr>
<tr>
<td>Experiment 1</td>
<td>16726±732</td>
<td>17353±1070</td>
<td>16485±1222</td>
</tr>
<tr>
<td>Adolescent (Ki-67)</td>
<td>14710±807</td>
<td>15931±736</td>
<td>16817±903</td>
</tr>
<tr>
<td>Experiment 1</td>
<td>16726±732</td>
<td>17353±1070</td>
<td>16485±1222</td>
</tr>
<tr>
<td>Adolescent (Ki-67)</td>
<td>16726±732</td>
<td>17353±1070</td>
<td>16485±1222</td>
</tr>
</tbody>
</table>
Table 2. Chronic treatment with fluoxetine or R121919 did not affect expression of BDNF mRNA measured by in situ hybridization in adult or adolescent rats. Data are presented as ROD normalized to vehicle levels for each area ± SEM. n=8-12 for all groups.
Figure 1.

Graph showing total BrdU+ cells with lithium p<0.0001.

Graph showing lithium p=0.0052 for dorsal BrdU+ cells.

Graph showing lithium p=0.0005 for ventral BrdU+ cells.

Experiment timeline:
- BrdU injection
- Drug treatment 21 days
- Sacrifice 2 hrs later
Figure 2.
Figure 3.